RecruitingFatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Eligible age
18–70 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Sponsor: The Third People's Hospital of Chengdu
You may qualify if…
- ✓ 1. Patients aged 18 years or older who provided written informed consent
- ✓ 2. Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD
- ✓ 3. Patients who schedule to undergo FibroScan examination
You may not qualify if…
- ✕ 1. Patients with ascites or pregnant women
- ✕ 2. Patients with any active implantable medical device (such as a pacemaker or defibrillator)
- ✕ 3. Patients who have undergone liver transplantation
- ✕ 4. Patients with cardiac failure and/or significant valvular disease
- ✕ 5. Patients with haemochromatosis
- ✕ 6. Patients who have refused to undergo LB or blood tests
- ✕ 7. Patients with a confirmed diagnosis of active malignancy, or other terminal disease
- ✕ 8. Patients participating in another clinical trial within the preceding 30 days
Source: ClinicalTrials.gov · NCT06720766 · last updated 2024-12-06